BVT Put 76 NVSEF 20.12.2024/ DE000VM36820 /
2024-08-20 7:44:32 PM | Chg.-0.001 | Bid8:45:00 AM | Ask8:45:00 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.030EUR | -3.23% | - Bid Size: - |
- Ask Size: - |
Novartis AG | 76.00 - | 2024-12-20 | Put |
GlobeNewswire
06-26
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
06-13
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
04-16
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
03-14
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
02-28
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
01-10
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
01-05
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
01-02
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
2023-12-11
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
2023-12-08
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire
2023-12-06
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
GlobeNewswire
2023-11-20
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH